SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-23-016696
Filing Date
2023-03-02
Accepted
2023-03-02 14:10:17
Documents
39
Period of Report
2022-12-31

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT f10q1222_rasnatherap.htm   iXBRL 10-Q 268928
2 CERTIFICATION f10q1222ex31-1_rasnatherap.htm EX-31.1 11115
3 CERTIFICATION f10q1222ex32-1_rasnatherap.htm EX-32.1 3484
  Complete submission text file 0001213900-23-016696.txt   1840217

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE rasp-20221231.xsd EX-101.SCH 25205
5 XBRL CALCULATION FILE rasp-20221231_cal.xml EX-101.CAL 17536
6 XBRL DEFINITION FILE rasp-20221231_def.xml EX-101.DEF 96233
7 XBRL LABEL FILE rasp-20221231_lab.xml EX-101.LAB 212236
8 XBRL PRESENTATION FILE rasp-20221231_pre.xml EX-101.PRE 103320
33 EXTRACTED XBRL INSTANCE DOCUMENT f10q1222_rasnatherap_htm.xml XML 124975
Mailing Address 420 LEXINGTON AVENUE SUITE 2525 NEW YORK NY 10170
Business Address 420 LEXINGTON AVENUE SUITE 2525 NEW YORK NY 10170 646-396-4087
Rasna Therapeutics Inc. (Filer) CIK: 0001582249 (see all company filings)

IRS No.: 392080103 | State of Incorp.: NV | Fiscal Year End: 0930
Type: 10-Q | Act: 34 | File No.: 333-191083 | Film No.: 23698004
SIC: 2834 Pharmaceutical Preparations